Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. (Q53507006)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Niels W C J van de Donk

15

object named as

N W C J van de Donk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

14

T Mutis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

3

H M Lokhorst

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

5

A C Bloem

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

I S Nijhof

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

B van Kessel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

J van Velzen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

R de Jong-Korlaar

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

H Yuan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

W A Noort

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

S K Klein

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

A C M Martens

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

P Doshi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

K Sasser

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

15 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

2039-2049

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Daratumumab granted breakthrough drug status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Cancer's true breakthroughs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Human CD38: a (r)evolutionary story of enzymes and receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

CD38 and chronic lymphocytic leukemia: a decade later

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Gene expression regulation by retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Molecular mechanism of human CD38 gene expression by retinoic acid. Identification of retinoic acid response element in the first intron

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Phosphatidylinositol 3-kinases are involved in the all-trans retinoic acid-induced upregulation of CD38 antigen on human haematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.123

Editorial: CD38 and retinoids: a step toward a cure

21 January 2018

1 reference

12 December 2020

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

1 reference

12 December 2020

Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL

1 reference

12 December 2020

Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha

1 reference

12 December 2020

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2015.123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25975191%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference